ALVO stock forecast, quote, news & analysis
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally... Show more
Why Alvotech (ALVO) Stock Is Up +20% in the Last 30 Days
Key Takeaways
- Alvotech (ALVO) shares have climbed roughly 20% over the last 30 days, moving from about $4.91 to around $5.89.
- The advance was driven by a rare Barclays double upgrade, Bank of America's Buy initiation, and FDA acceptance of the company's AVT80 biosimilar application.
- Over the last quarter the stock has risen about 69%, rebounding sharply from a mid-2026 low as manufacturing and regulatory overhangs eased.
- Investors are positioning ahead of anticipated FDA decisions in the fourth quarter of 2026 on biosimilars to Simponi, Eylea, and Prolia/Xgeva.
- Management has reaffirmed full-year 2026 guidance of $650–$700 million in revenue and $180–$220 million in adjusted EBITDA.
Alvotech (ALVO) Company Overview and Market Position
Alvotech is a global biotechnology company focused exclusively on the development and manufacturing of biosimilar medicines. Founded by Robert Wessman, the company pursues lower-cost versions of blockbuster biologic therapies through a fully integrated platform spanning research and development, regulatory affairs, and large-scale manufacturing.
Alvotech currently has five biosimilars approved and marketed across multiple markets, including biosimilars to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept), and Prolia/Xgeva (denosumab). Its disclosed pipeline includes candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. The company distributes through a network of commercial partners, including Teva (TEVA), Sandoz, and Dr. Reddy's Laboratories, to reach the United States, Europe, Japan, and other global markets.
Alvotech (ALVO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ALVO has advanced approximately 20%, rising from a closing price near $4.91 in late August to about $5.89. The move has been characterized by sharp, news-driven gains rather than a steady grind higher, including a 7.9% single-session surge in mid-September.
The quarterly picture is even stronger. Roughly three months earlier, the stock closed near $3.48, meaning the shares have gained about 69% over the trailing quarter. This rebound is notable because the stock spent much of the first half of 2026 under pressure, trading near its 52-week low of $2.94 as investors weighed manufacturing remediation and delayed U.S. regulatory approvals.
What Drove ALVO Stock Price in the Last 30 Days
Several verified catalysts powered the recent 20% advance. The most prominent was a rare double upgrade from Barclays in mid-September, when analyst Glen Santangelo lifted the stock to Overweight from Underweight and raised the price target to $8 from $4, citing confidence that the FDA will approve three biosimilars later this year. The shares rose 7.9% on the announcement, their largest single-day gain since the prior December.
Earlier in the period, Bank of America initiated coverage with a Buy rating and a $7 price objective, framing the company as approaching an "important inflection point" as the debate shifts from regulatory risk toward commercial execution. Separately, the FDA accepted Alvotech's Biologics License Application for AVT80, a proposed biosimilar to Entyvio (vedolizumab), in a prefilled syringe and pen format. Together, these developments reinforced investor optimism around the company's near-term approval pipeline.
What Drove ALVO Stock Performance Over the Last Quarter
The broader quarterly rally reflects a steady unwinding of the two concerns that weighed on the stock through early 2026: manufacturing compliance and U.S. approval timing. In July, the FDA formally closed its inspection of Alvotech's Reykjavik facility with a Voluntary Action Indicated (VAI) classification, clearing a key obstacle to pending applications.
Around the same time, the company resubmitted U.S. Biologics License Applications for AVT05 (a biosimilar to Johnson & Johnson's (JNJ) Simponi), AVT06 (a biosimilar to Regeneron's (REGN) Eylea), and AVT03 (a biosimilar to Amgen's (AMGN) Prolia/Xgeva). Leadership also changed, with Lisa Graver becoming CEO in late March 2026, and the company strengthened its balance sheet with roughly $165 million in equity proceeds and a $75 million term loan. Although first-half 2026 revenue declined year over year due to a manufacturing slowdown, management reaffirmed its full-year outlook, which helped stabilize sentiment into the second half.
Trending AI Robots
For traders seeking to complement their own analysis, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading tools. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant robots are featured in this section. The bots vary considerably in strategy, timeframe, and performance metrics, allowing users to explore approaches aligned with different trading styles. Exploring the page can provide additional perspective on how algorithmic strategies are positioned across the market.
ALVO Stock Forecast Drivers: What Investors Should Watch Next
The primary near-term catalyst is the FDA's review of Alvotech's biosimilar applications for Simponi, Eylea, and Prolia/Xgeva, with regulatory decisions expected on or before December 4, 2026. Approval timing and any related intellectual-property or litigation outcomes will shape the U.S. launch trajectory for these products.
Investors are also likely to monitor third-quarter financial results and management's commentary on manufacturing ramp-up, given that the company expects the fourth quarter to be its strongest as supply normalizes. Additional watch items include progress on the Entyvio biosimilar program, the high-dose Eylea candidate, and the FUJIFILM Biotechnologies partnership that is intended to add U.S.-based manufacturing capacity beginning in late 2027. Competitive pricing dynamics and reimbursement in the biosimilar market remain important variables that could influence both revenue growth and margins.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALVO in +10.11% Uptrend, rising for three consecutive days on September 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ALVO advanced for three days, in 187 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on ALVO as a result. In 64 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The 50-day moving average for ALVO moved above the 200-day moving average on September 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Aroon Indicator entered an Uptrend today. In 106 of 160 cases where ALVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALVO moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 21 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for ALVO turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 31 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
ALVO broke above its upper Bollinger Band on September 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (43.873). P/E Ratio (42.450) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric